Corona in general

Researchers screened BNT162b2 COVID-19 vaccine recipients and cloned broadly neutralizing antibodies from an elite vaccinee. // 10.11.2022

Introduction COVID-19 pandemic caused by SARS-CoV-2 has become a global health challenge. SARS-CoV-2 can infect host cells via the ACE2 receptor, which is widely expressed in the corpus cavernosum, testis and male reproductive tract, and participates in erection, spermatogenesis and androgen metabolism. Also, the immune response and persistent fever resulting from COVID-19 may lead to damage of the testicular activity, consequently compromising male fertility. Methods and analysis PubMed, MEDLINE, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, China Science and Technology Journal database, Chinese Biomedical Databases and Wanfang Data will be systematically searched for observational studies (case–control and cohort) published up to March 2021 in English or in Chinese literature on the impacts of COVID-19 and SARS-CoV-2 on male reproductive function. This protocol will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines and Meta-analysis of Observational Studies in Epidemiology. The primary outcome will be semen parameters, and the additional outcomes will include: (a) detection of SARS-COV-2 in semen, (b) male sexual hormones, (c) sperm DNA fragmentation index, (d) erectile function, (e) evaluation of testis and also the male genital tract. Two reviewers will independently extract data from the included studies based on a predesigned data extraction form. The risk of bias of included studies will be evaluated through the Newcastle-Ottawa Scale for observational studies. Review Manager software V.5.3 will be used for statistical analysis. Q statistic and I² test will be performed to assess the heterogeneity among studies. Sensitivity analysis will be used to explore the robustness of pooled effects. We will use the Grading of Recommendations Assessment, Development and Evaluation system to assess the quality of evidence. Ethics and dissemination Ethical approval is not required and results will be published in a peer-reviewed journal. PROSPERO registration number CRD42021245161.

A new study investigated SARS-CoV-2 cell-to-cell transmission in the context of cell-free infection and compared it to SARS-CoV. // 10.1.2022

Researchers demonstrate the role of integrins in the establishment of the SARS-CoV-2 infection. // 9.1.2022

Turun yliopiston professorit Jarmo Oksi ja Ville Peltola seuraavat koronaepidemian kehitystä Turun yliopistollisessa keskussairaalassa, jossa tilanne on vielä suhteellisen rauhallinen. // 6.5.2020

Researchers compare the number, types, and risk for complications among COVID-19 and influenza patients using claims data. // 9.1.2022

New research can confirm that while some of the response from monocytes to SARS-CoV-2 is generic to virus infection, most of it SARS-CoV-2 specific, especially proinflammatory responses. // 7.1.2022

A new study aimed to explore whether there is a way to induce the production of potent neutralizing antibodies capable of neutralizing all SARS-CoV-2 variants - including Omicron. // 6.1.2022

Researchers explored the presence of coronavirus receptors in the glossopharyngeal and vagal cranial nerves. // 6.1.2022

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate. // 6.1.2022

New research recently unveiled the utility of melatonin and melatonin-derived medicines in reducing brain entry of severe acute respiratory syndrome coronavirus 2 and subsequently preventing long-term neurological consequences of coronavirus disease 2019. // 6.1.2022

A recent editorial in the journal Nutrients emphasizes how efficacious non-pharmacological interventions in conjunction with the promotion of healthy lifestyle and dietary patterns may improve overall health status and reduce the risk of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as the potential adverse effects of coronavirus disease 2019 (COVID-19). // 6.1.2022

The LIVE-AIR phase 3 clinical trial is associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody lenzilumab in COVID-19 patients with decreased oxygen saturation. // 6.1.2022

Researchers aim to understand the potential benefits of mAbs in preventing and treating SARS-CoV-2 infection. // 5.1.2022

New study results suggest that integrin inhibitors have the potential to both prevent infection with SARS-CoV-2, including the Delta and Omicron variants, and to decrease TGF-β levels, resulting in a decrease in COVID-19 severity, hospitalization, and death, especially in vulnerable and unvaccinated populations. // 5.1.2022

The frequency of SARS-CoV-2 breakthrough infections in fully vaccinated individuals increased with the emergence of the Delta variant, particularly with longer time from vaccine completion. // 4.1.2022

Researcers determine the risk of symptomatic and asymptomatic SARS-CoV-2 infection on post-acute cardiovascular events and all-cause mortality. // 4.1.2022

Researchers discuss the findings of previous studies on the role of SARS-CoV-2 infection in the progression of Alzheimer's Disease. // 4.1.2022

A cross-sectional report from Israel demonstrated the protective effect of BNT162b2 mRNA vaccine (Pfizer–BioNTech) even after mild to moderate COVID-19). // 4.1.2022

A large international team of researchers has conducted a crowdsourced cross-sectional study, in which they have investigated the reliability of the olfactory loss (or loss of smell, or anosmia) as a predictor of coronavirus disease 19 (COVID-19). // 30.12.2021

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections. // 30.12.2021

Background Pronounced sex differences in the susceptibility and response to SARS-CoV-2 infection remain poorly understood. Emerging evidence has highlighted the potential importance of autoimmune activation in modulating the acute response and recovery trajectories following SARS-CoV-2 exposure. // 30.12.2021

Researchers carried out an analytical susceptibility test with cultured SARS-CoV-2 Omicron variant in seven antigen-detecting rapid diagnostic (Ag-RDTs). // 29.12.2021

New study findings reveal that saliva samples are more useful than mid-turbinate samples for the accurate detection of omicron infection. // 29.12.2021

In a new study, researchers reviewed research on the role that selenium could play in protecting individuals against coronavirus disease 2019. // 29.12.2021

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity. // 29.12.2021

A new study suggests the Omicron (B.1.1.529) variant is not as infectious as scientists initially assumed. // 29.12.2021

Researchers conducted a genomic sequencing and epidemiological correlation analysis of the SARS-CoV-2 Omicron variant. // 29.12.2021

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. // 28.12.2021

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate. // 28.12.2021